Revolution Medicines Soars 5.76% on Bullish Analyst Sentiment

Revolution Medicines' stock surged 5.76% in pre-market trading on April 8, 2025, reflecting a significant uptick in investor sentiment.

Analysts have been actively revising their price targets for Revolution Medicines. Stifel recently lowered its target to $64 while maintaining a Buy rating. Meanwhile, H.C. Wainwright adjusted its target to $73, also keeping a Buy rating despite the company's recent performance.

Despite the positive analyst sentiment, some analysts have expressed caution. One report rated the company as a SELL, citing poor fundamentals and speculative investment risks. However, the consensus rating remains a Buy, with a target price of $65.23, indicating a potential upside of 108.27%.